OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, Epilog.us [http://www.Epilog.us], now features a panel discussion of leading experts on the role of rational polytherapy in the treatment of patients with epilepsy, led by Dr. Barry Gidal, Professor of Pharmacy and Neurology/Division Chair, University of Wisconsin. Dr. Gidal also brings forward discussion on the mechanism of action of specific antiepileptic drugs (AEDs). Additional topics include: AED pharmacokinetics; patient adherence and AEDs; and drug interactions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59891-upsher-smith-epilog-us-pharmacodynamics-of-antiepileptic-drugs-aeds
With the ultimate goal of preventing half a million teens from abusing medicine within five years, The Partnership at Drugfree.org will launch The Medicine Abuse Project during the week of September 23-29, 2012. The launch week will kick start a multi-year effort to help educate parents, teens and the public about the dangers of medicine abuse and unite parents, educators, health care providers, coaches, government officials, law enforcement officers and other partners to help save lives.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54143-the-partnership-at-drugfree-org-medicine-abuse-project-teen-education
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced at the mHealth Summit that it is expanding the beta program for its Patient Instructions feature, which enables physicians who use Medscape Mobile to securely send education and instructions on thousands of conditions, procedures and drugs to their patients who use the WebMD app for iPhone, or access WebMD on a PC or other mobile device. The company also previewed a forthcoming version of its WebMD app that leverages the 2net™ Platform from Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated (NASDAQ: QCOM), to enable health-conscious consumers to access and manage wireless health data from a wide array of fitness, wellness and medical devices directly from the app.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60050-webmd-accelerates-consumer-provider-connectivity-personalized-mobile-app
Vioxx Settlement
This is an important announcement for consumers about the prescription drug Vioxx. Vioxx was a drug commonly used to treat pain and inflammation in adults with arthritis.
A settlement was reached with the manufacturer of Vioxx and will provide refunds to anyone who paid for the medication. Consumers are eligible to get $50 or more. Personal injury claims related to this drug are not included in this settlement.
The deadline to file a claim is approaching – claims must be filed by May 6, 2014.
Details are available at http://www.VioxxSettlement.com or by calling 1-866-439-6932.
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Globally, 1.2 billion people have no access to electricity. On the occasion of VELUX 75th anniversary the company decided to address this issue. Together with the social business Little Sun and the NGO Plan International they are collaborating to bring clean, reliable and affordable light to off-grid regions in Zambia, Sierra Leone and Zimbabwe.
14,500 Natural Light lamps from the VELUX Group have now arrived in Africa and the first recipients can already look forward to a better quality of life.
Among them are young girls between 10 and 18 years of age who live in a safe house in the slum area Mntendere in the Zambian capital Lusaka.
"The lamps mean the girls can do their homework when they get back from school and can feel safer at night, instead of huddling together in the dark after sunset. And it’s particularly important for our children that they feel safe – many are carrying the mental baggage such as the trauma of violence, rape or drugs," says safe house manager Verann Delarey.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7769151-velux-natural-light-and-life-zambia/
